GNBTQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GNBTQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Generex Biotechnology's average Accounts Payable for the three months ended in Apr. 2021 was $40.14 Mil. Generex Biotechnology's Cost of Goods Sold for the three months ended in Apr. 2021 was $0.07 Mil. Hence, Generex Biotechnology's Days Payable for the three months ended in Apr. 2021 was 55,495.21.
The historical rank and industry rank for Generex Biotechnology's Days Payable or its related term are showing as below:
Generex Biotechnology's Days Payable increased from Apr. 2020 (17,803.50) to Apr. 2021 (55,495.21). It may suggest that Generex Biotechnology delayed paying its suppliers.
The historical data trend for Generex Biotechnology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generex Biotechnology Annual Data | |||||||||||||||||||||
Trend | Jul11 | Jul12 | Jul13 | Jul14 | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | |||||||||||
Days Payable | Get a 7-Day Free Trial | - | - | - | 1,134.46 | 12,164.15 |
Generex Biotechnology Quarterly Data | ||||||||||||||||||||
Jul16 | Oct16 | Jan17 | Apr17 | Jul17 | Oct17 | Jan18 | Apr18 | Jul18 | Oct18 | Jan19 | Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | |
Days Payable | Get a 7-Day Free Trial | 17,803.50 | 12,566.23 | 113,808.59 | 31,625.08 | 55,495.21 |
For the Biotechnology subindustry, Generex Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Generex Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Generex Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Generex Biotechnology's Days Payable for the fiscal year that ended in Jul. 2020 is calculated as
Days Payable (A: Jul. 2020 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Jul. 2019 ) | + | Accounts Payable (A: Jul. 2020 )) | / | count ) | / | Cost of Goods Sold (A: Jul. 2020 ) | * | Days in Period |
= | ( (14.684 | + | 23.908) | / | 2 ) | / | 0.579 | * | 365 |
= | 19.296 | / | 0.579 | * | 365 | ||||
= | 12,164.15 |
Generex Biotechnology's Days Payable for the quarter that ended in Apr. 2021 is calculated as:
Days Payable (Q: Apr. 2021 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Jan. 2021 ) | + | Accounts Payable (Q: Apr. 2021 )) | / | count ) | / | Cost of Goods Sold (Q: Apr. 2021 ) | * | Days in Period |
= | ( (39.317 | + | 40.961) | / | 2 ) | / | 0.066 | * | 365 / 4 |
= | 40.139 | / | 0.066 | * | 365 / 4 | ||||
= | 55,495.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Generex Biotechnology's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Prioletti Mark Joseph Se | director | 1121 PALMER COURT CRYSTAL LAKE IL 60014 |
Salvo Lawrence Anthony Sr | director | 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139 |
Harold Gray Haines | other: Consultant | 11511 SW 127TH ST MIAMI FL 33176 |
Mark Fletcher | officer: EVP General Counsel &Secretary | 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3 |
Brian Mcgee | director | 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000 |
Anderson James H Jr. | director | 33 HARBOUR SQUARE TORONTO A6 M5J2G2 |
Mark Corrao | officer: CFO & Treasurer | 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825 |
Purcell Richard David Jr. | director, officer: SVP of Research & Drug Develop | 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704 |
Gary Herbert Lyman | director | 10102 USA TODAY WAY MIRAMAR FL 33025 |
Kevin Centofanti | director | 10102 USA TODAY WAY MIRAMAR FL 33025 |
Andrew Ro | director, officer: SVP & Chief Investment Officer | 10102 USA TODAY WAY MIRAMAR FL 33025 |
David Brusegard | officer: Chief Operating Officer | 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3 |
Stephen Fellows | officer: Chief Financial Officer | 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2 |
Hofe Eric Von | director, officer: President of Subsidiary | 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3 |
John P Barratt | director | 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1 |
From GuruFocus
By Marketwired Marketwired • 05-06-2021
By Marketwired Marketwired • 02-24-2021
By Marketwired Marketwired • 10-06-2020
By Marketwired Marketwired • 07-26-2021
By Marketwired Marketwired • 05-10-2021
By Marketwired Marketwired • 05-11-2021
By Marketwired Marketwired • 11-03-2020
By Marketwired Marketwired • 11-04-2020
By Marketwired Marketwired • 10-02-2020
By Marketwired Marketwired • 04-27-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.